Cargando…

Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement

BACKGROUND: Liver fibrosis is the most important prognostic factor in chronic hepatitis C virus (HCV) patients, and Egypt shows the highest worldwide HCV prevalence with genotype-4 pre-dominance. The aim of this study was to investigate the degree of liver stiffness measurement (LSM) improvement aft...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tag-Adeen, Mohammed, Sabra, Ahlam Mohamed, Akazawa, Yuko, Ohnita, Ken, Nakao, Kazuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638573/ https://www.ncbi.nlm.nih.gov/pubmed/29062242 http://dx.doi.org/10.2147/HMER.S142600

Ejemplares similares

An unusual presentation of adult T-cell leukemia/lymphoma
por: Tag-Adeen, Mohammed, et al.
Publicado: (2018)

Augmenting central arterial stiffness following eradication of HCV by direct acting antivirals in advanced fibrosis patients
por: Cheng, Pin-Nan, et al.
Publicado: (2019)

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals
por: Lynch, Erica Nicola, et al.
Publicado: (2023)

Impact of hepatitis C virus eradication with direct-acting antivirals on glycidic metabolism
por: Sparvoli, Jucéli Márcia Hendges, et al.
Publicado: (2022)

The impact of single-nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct-acting antiviral drugs for hepatitis C infection
por: Matsumoto, Kosuke, et al.
Publicado: (2022)

Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct‐acting antivirals
por: Tachi, Yoshihiko, et al.
Publicado: (2017)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals
por: Tajiri, Kazuto, et al.
Publicado: (2023)

Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
por: Lee, Hye Won, et al.
Publicado: (2020)

Endoscopic submucosal dissection of the pharyngeal region using anchored hemoclip with surgical thread: A novel method
por: Minami, Hitomi, et al.
Publicado: (2016)

Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms
por: Nardelli, Silvia, et al.
Publicado: (2019)

Eradication of hepatitis C virus with direct‐acting antivirals improves glycemic control in diabetes: A multicenter study
por: Takahashi, Hirokazu, et al.
Publicado: (2020)

Peripheral neuropathy after viral eradication with direct‐acting antivirals in chronic HCV hepatitis: A prospective study
por: Zanone, Maria M., et al.
Publicado: (2021)

Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2020)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
por: Armando, Calogero, et al.
Publicado: (2019)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
por: Zanaga, L.P., et al.
Publicado: (2016)

Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct‐Acting Antivirals
por: Ioannou, George N., et al.
Publicado: (2019)

Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals
por: Cerrito, Lucia, et al.
Publicado: (2021)

Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience
por: Alkadi, Mohamad M., et al.
Publicado: (2020)

Erratum to “Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients”
por: Calogero, Armando, et al.
Publicado: (2019)

Liver stiffness measurement and spleen diameter as predictors for the presence of esophageal varices in chronic hepatitis C patients
por: Tag-Adeen, Mohammed, et al.
Publicado: (2017)

Economic evaluation of direct‐acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore
por: Wong, Yu‐Jun, et al.
Publicado: (2019)

Changes in the Serum Hepcidin-to-ferritin Ratio with Erythroferrone after Hepatitis C Virus Eradication Using Direct-acting Antiviral Agents
por: Inomata, Shinjiro, et al.
Publicado: (2019)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

Polyglycolic Acid Felt Sealing Method for Prevention of Bleeding Related to Endoscopic Submucosal Dissection in Patients Taking Antithrombotic Agents
por: Fukuda, Hiroko, et al.
Publicado: (2016)

Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China
por: Wang, Xiaozhong, et al.
Publicado: (2021)

Experience with direct-acting antivirals in genotype 1–5 infected chronic hepatitis C patients in Turkey
por: Sahin, Ahmet, et al.
Publicado: (2023)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

A case series evaluating the impact of Hepatitis C eradication using direct acting antivirals on primary biliary cholangitis-associated autoimmunity
por: Nguyen, Henry H., et al.
Publicado: (2018)

The Association between the Platelet Count and Liver Volume in Compensated Cirrhosis Patients after the Eradication of Hepatitis C virus by Direct-acting Antivirals
por: Seko, Yuya, et al.
Publicado: (2020)

Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort
por: Quaranta, Maria Giovanna, et al.
Publicado: (2021)

Bamboo Joint-Like Appearance of the Stomach: A Stable Endoscopic Landmark for Crohn’s Disease Regardless of Anti-Tumor Necrosis Factor alpha Treatment
por: Hashiguchi, Keiichi, et al.
Publicado: (2014)

Hepatitis B Co-Infection Has Limited Impact on Liver Stiffness Regression in Chronic Hepatitis C Patients Treated with Direct-Acting Antivirals
por: Hsu, Cheng-Er, et al.
Publicado: (2022)

Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice
por: Takahara, Ikuko, et al.
Publicado: (2017)

The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals
por: Lee, Yu-Chi, et al.
Publicado: (2019)

Correction: Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice
por: Takahara, Ikuko, et al.
Publicado: (2020)

Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis
por: Kawagishi, Naoki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_su5imgrnicoij6v49vjnu2sbhu